MedTrace Logo

A Study of Tumor Imaging With Multispectral Optoacoustic Tomography

NCT05488483 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2026-02-19

No results posted yet for this study

Summary

Participants in this study will have Multispectral Optoacoustic Tomography/MSOT imaging of both breasts immediately before their ultrasound-guided breast biopsy procedure begins. After the MSO imaging is completed, participation in the study will end.

Conditions

Interventions

DIAGNOSTIC_TEST

Multispectral Optoacoustic Tomography Imaging

Each participants will undergo MSOT imaging of the suspicious breast tumor detected with ultrasound imaging and any additional lesion present in either breast before undergoing ultrasound-guided breast biopsy as the standard of care. Melanoma participants with pathologically confirmed ITM will undergo MSOT imaging following physical exam and biopsy. Melanoma patients receiving immunotherapy will undergo MSOT imaging prior to and following immunotherapy.

Sponsors & Collaborators

Principal Investigators

  • Jan Grimm, MD, PhD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-27
Primary Completion
2026-07-27
Completion
2026-07-27

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05488483 on ClinicalTrials.gov